Abstract
Colorectal cancer (CRC) remains the third most prevalent cancer and the fourth most common cause of cancer-related mortality (Mármol et al., 2017). In recent years, the incidence and mortality rate of CRC has been rampant in several developing countries (Benarba et al., 2018). Although it is feasible to combat some cancers, this does not hold true for CRC due to its asymptomatic nature in the early stages, hence it is often diagnosed after symptoms become noticeable (Mishra et al., 2013). There are several therapeutic methods available for CRC management, such as surgical excision, chemotherapy and radiotherapy (Hodgkinson et al., 2017). However, these therapeutic modalities have rarely yielded good prognosis in patients and have detrimental side effects (Mishra et al., 2013). Moreover, evolving resistance of cancer cells towards chemotherapeutic and biological drugs, as well as non-specific toxicity of these drugs on healthy tissues creates the need to explore other methods of CRC therapy (Hodgkinson et al., 2017)...
M.Tech. (Biomedical Technology)